This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

MyMatrixx Dramatically Reduces Opioid Spend For Catastrophic Claim

TAMPA, Fla., Feb. 4, 2013 /PRNewswire/ -- myMatrixx, a pharmacy benefit management and ancillary medical services company serving workers' compensation announced today the release of a new case study resulting in savings of over $250,000 per year for one claimant. The study titled "Unmanageable or Simply Unmanaged? A Look Inside An Opioid Drug Treatment Case" reviews a clinical intervention with a catastrophic case including multiple opioids totaling over $27,000 a month. The case was brought to myMatrixx by Safety National who was concerned about the cost of this regimen as well as health risks for the injured worker.

(Logo: http://photos.prnewswire.com/prnh/20111005/FL81065LOGO )

During the twenty three year period of the claim, the treatment plan progressed from addressing a lower back strain injury to managing chronic pain syndrome. Opioid pain therapy was the primary course of treatment prescribed with a total of eight medications. Actiq was one of the opioids prescribed and attributed to 80% of the monthly costs alone. Additionally, the prescribed daily morphine equivalent dose (MED) was ~1331 mg, 13 times over the recommended limit and posed a serious risk to the patient.

After reviewing the drug therapy, myMatrixx's clinical team consulted with the physician who agreed the treatment was out of the ordinary for the injury. He decided to discontinue the use of Actiq and pursue trials of generic alternatives for some of the other drugs in the regimen. The immediate result was seen in the estimated annual savings of over $250,000 for this one claim. Mitch Neuhaus, CPCU, Vice President of Claims for Safety National stated, "The claims administrator and defense counsel had tried for years to change the drug regimen without success. We would never have been able to get this patient off of Actiq without myMatrixx's efforts."

"In many cases making just one change in drug therapy can have a huge impact on a claim," Phil Walls, R.Ph., Chief Clinical and Compliance Officer with myMatrixx added. "In this case the impact improved the patient's care by reducing the serious risk of overdose while also delivering a significant savings to our client."

To read the case study in its entirety, visit www.mymatrixx.com.  For more information on myMatrixx's Clinical Program, contact ltaylor@mymatrixx.com.

About myMatrixx

myMatrixx® is a full-service pharmacy and ancillary medical benefit management company focused on the workers' compensation market. By combining advanced technology, clinical expertise and comprehensive reporting, myMatrixx simplifies the management of claims. Our results driven solutions deliver reduced costs for our clients and improve outcomes for their injured workers. For more information, visit www.mymatrixx.com.

Contact: Lori Taylor, Director of Marketing and Communications(877) 804-4900, ext 136 or ltaylor@mymatrixx.com

SOURCE myMatrixx

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs